熱門資訊> 正文
专注于帕金森氏症的Serina Therapeutics与Element Injects达成合作伙伴关系
2024-05-15 20:26
- Enable Injections and Serina Therapeutics (NYSE:SER) Wednesday announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s disease.
- SER-252 is an investigational apomorphine therapy developed with Serina’s (SER) POZ platform and designed to provide continuous dopaminergic stimulation.
- CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease, the company said.
- Preclinical studies support the potential of SER-252 to provide CDS without skin reactions. Serina (SER) plans to advance SER-252 to clinical testing in 2025, it said.
- Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies in combination with the enFuse technology.
- Under the terms of the agreement, Serina (SER) will obtain a worldwide, exclusive license to the enFuse platform for an upfront and future milestone payments. Enable will also be entitled to product sales and single digit royalties.
- Source: Press Release
More on AgeX Therapeutics
- Financial information for AgeX Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。